{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=39",
    "query": {
      "intervention": "Safety Control",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 14125,
    "total_pages": 1413,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T01:14:56.238Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06503731",
      "title": "A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antibody-mediated Rejection"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC - prefilled syringe",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo PH20 SC - prefilled syringe",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 33,
      "start_date": "2024-08-30",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06503731"
    },
    {
      "nct_id": "NCT01368445",
      "title": "A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "azelastine hydrochloride 0.15% Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "azelastine hydrochloride 0.15% and Placebo",
          "type": "DRUG"
        },
        {
          "name": "Azelastine 0.1%, Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Meda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 617,
      "start_date": "2006-08",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2011-10-06",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 30,
      "location_summary": "Fountain Valley, California • Long Beach, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01368445"
    },
    {
      "nct_id": "NCT05896527",
      "title": "A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "DC-806",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 229,
      "start_date": "2023-05-02",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 13,
      "location_summary": "Fountain Valley, California • Santa Monica, California • Coral Gables, Florida + 10 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05896527"
    },
    {
      "nct_id": "NCT00152386",
      "title": "A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Certolizumab pegol (CDP870)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 950,
      "start_date": "2005-02",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-01",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 26,
      "location_summary": "Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00152386"
    },
    {
      "nct_id": "NCT06546670",
      "title": "A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "ITU512",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "12 Years to 55 Years"
      },
      "enrollment_count": 161,
      "start_date": "2024-08-15",
      "completion_date": "2030-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06546670"
    },
    {
      "nct_id": "NCT03168854",
      "title": "Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum Infection"
      ],
      "interventions": [
        {
          "name": "Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Malaria challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-07-26",
      "completion_date": "2019-08-16",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03168854"
    },
    {
      "nct_id": "NCT02873156",
      "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "E2027",
          "type": "DRUG"
        },
        {
          "name": "E2027 matched placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 74,
      "start_date": "2016-08-10",
      "completion_date": "2017-11-29",
      "has_results": false,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02873156"
    },
    {
      "nct_id": "NCT03364153",
      "title": "Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stargardt's Macular Dystrophy"
      ],
      "interventions": [
        {
          "name": "avacincaptad pegol",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 121,
      "start_date": "2018-01-12",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03364153"
    },
    {
      "nct_id": "NCT03325075",
      "title": "Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chikungunya Virus"
      ],
      "interventions": [
        {
          "name": "VAL-181388",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-07-19",
      "completion_date": "2019-03-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-10",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03325075"
    },
    {
      "nct_id": "NCT02173301",
      "title": "A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "XP23829 400 mg QD",
          "type": "DRUG"
        },
        {
          "name": "XP 23829 800 mg QD",
          "type": "DRUG"
        },
        {
          "name": "XP23829 400 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2014-06",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2022-04-12",
      "last_synced_at": "2026-11-04T01:14:56.238Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02173301"
    }
  ]
}